Table 1.
Characteristics of patients.
Table 2.
Plasma hsCRP levels and neurological improvement during hospitalization.
Table 3.
Plasma hsCRP levels and neurological deterioration during hospitalization.
Table 4.
Plasma hsCRP levels and poor functional outcome at discharge and at 3 months.
Table 5.
Plasma hsCRP levels and clinical outcomes in patients without post-stroke acute infections.
Fig 1.
Multivariable-adjusted odds ratio and 95% confidence interval of each hsCRP quartile for poor functional outcome at 3 months are shown according to subgroups. Q1–Q4 indicate the four groups according to the quartile of hsCRP (mg/L). The multivariable model included age, sex, baseline NIHSS score, stroke subtypes, hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, smoking, drinking, chronic kidney disease, body mass index, intravenous thrombolytic therapy and endovascular therapy, and acute infections. Subgroups included age (≥70 years or <70 years), stroke subtypes (cardioembolic or others), and stroke severity (baseline NIHSS score 0–4 or NIHSS score ≥5). P for heterogeneity (Pheterogeneity) was calculated by means of the interaction term.